Rapid antidepressant effects of anesthetic and perioperative drugs: mechanisms, clinical evidence, and translational boundaries
Frontiers in Psychiatry · 17.11.2026 · 17
DOI: 10.3389/fpsyt.2026.1995965 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Psychiatry, online erschienen am 17.11.2026. Verfasst von Xinyi Wang und 3 weiteren Autor:innen. Die Arbeit nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Rapid symptom relief remains an important unmet need in treatment-resistant depression (TRD) and in depressive episodes accompanied by acute suicidal ideation or behavior. This narrative review examines anesthetic and perioperative drugs that have been proposed as rapid-acting antidepressants. N-methyl-D-aspartate (NMDA)-receptor blockade, increased α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) throughput, and brain-derived neurotrophic factor (BDNF)–tropomyosin receptor kinase B (TrkB)–mechanistic target of rapamycin complex 1 (mTORC1) signaling provide a predominantly preclinical account of rapid synaptic plasticity, and randomized trials show improvement in depressive symptoms within hours to days. Ketamine and esketamine have the strongest evidence, with variable response- and remission-rates and limited sustained duration of benefit across studies. Intravenous ketamine can rapidly reduce suicidal ideation, but it does not replace comprehensive suicide-prevention care. Intranasal esketamine reduces depressive symptoms in TRD and in adults with major depressive disorder (MDD) and acute suicidal ideation or behavior; a separate effect on suicidal ideation or suicide prevention has not been demonstrated. Nitrous oxide has encouraging phase 2 evidence, though the primary-outcome point estimate was modest with wide confidence intervals and narrowly missed conventional statistical significance. Evidence for propofol and volatile anesthetics remains limited to small experimental studies. Tramadol is better viewed as a pharmacologic clue than as an antidepressant treatment. Clinical translation requires agent-specific monitoring, defined maintenance and stopping rules, and attention to cardiovascular, respiratory, cognitive, urinary, hepatic, and misuse risks. This is a narrative review without formal meta-analysis; findings should be interpreted considering heterogeneous trial designs and variable sample sizes.
Zitieren
APA
Wang, X., Ma, J., Ren, S., & Hu, L. (2026). Rapid antidepressant effects of anesthetic and perioperative drugs: mechanisms, clinical evidence, and translational boundaries. Frontiers in Psychiatry, 17. https://doi.org/10.3389/fpsyt.2026.1995965
Vancouver
Wang X, Ma J, Ren S, Hu L. Rapid antidepressant effects of anesthetic and perioperative drugs: mechanisms, clinical evidence, and translational boundaries. Frontiers in Psychiatry. 2026;17. doi:10.3389/fpsyt.2026.1995965
BibTeX
@article{Wang2026,
author = {Wang, Xinyi and Ma, Jinqi and Ren, Shujun and Hu, Li},
title = {Rapid antidepressant effects of anesthetic and perioperative drugs: mechanisms, clinical evidence, and translational boundaries},
journal = {Frontiers in Psychiatry},
year = {2026},
volume = {17},
doi = {10.3389/fpsyt.2026.1995965}
}
EUVIMED